We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ZimVie Inc | NASDAQ:ZIMV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.34 | 2.20% | 15.82 | 15.25 | 16.55 | 15.95 | 15.48 | 15.48 | 143,539 | 22:30:00 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
ZimVie Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
98888T107
(CUSIP Number)
December 31, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ | Rule 13d-1(b) |
☐ | Rule 13d-1(c) |
☒ | Rule 13d-1(d) |
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
NAME OF REPORTING PERSON I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON (Entities Only) Zimmer Biomet
Holdings, Inc. 13-4151777 CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (a) ☐ (b) ☐ SEC USE ONLY CITIZENSHIP OR PLACE OF
ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 0 (See Note 1) SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 5,131,946 (See Note 2) SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,131,946 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9) 19.7% (See Note 3) TYPE OF REPORTING
PERSON CO Note 1: On March 1, 2022, Zimmer Biomet Holdings, Inc. (Zimmer Biomet) completed the separation of
ZimVie Inc. (the Company) through the distribution of 80.3% of the outstanding shares of common stock, par value $0.01 per share of the Company (Company Common Stock) to Zimmer Biomets stockholders (the
Spinoff). Immediately following the Spinoff, Zimmer Biomet directly owned 5,131,946 shares, or 19.7%, of the outstanding shares of Company Common Stock. Pursuant to a Stockholder and Registration Rights Agreement, dated as of
March 1, 2022 (the Stockholder and Registration Rights Agreement), between Zimmer Biomet and the Company, Zimmer Biomet granted to the Company a proxy to vote the shares of Company Common Stock owned by Zimmer Biomet immediately
after the Spinoff in proportion to the votes cast by the Companys other stockholders. As a result, Zimmer Biomet does not exercise voting power over any of the shares of Company Common Stock it directly owns.
Note 2: On September 1, 2022, Zimmer Biomet entered into a forward exchange agreement and pledge
agreement (collectively the Forward Exchange Agreement) with a third-party financial institution to deliver to them all of its 5,131,946 shares of Company Common Stock in the first quarter of 2023. Zimmer Biomet pledged all 5,131,946 of
its shares of Company Common Stock to the financial institution as collateral for its obligations under the Forward Exchange Agreement and under a short-term credit agreement Zimmer Biomet entered into with the same third-party financial institution
on August 31, 2022 (the Short-Term Loan). Upon settlement of the Forward Exchange Agreement and the Short-Term Loan, Zimmer Biomet will transfer all of its shares of Company Common Stock to the financial institution counterparty to
settle the Forward Exchange Agreement. Note 3: The denominator for this calculation is based on 26,088,272 shares of Company Common Stock
outstanding as of November 4, 2022, as reported in the Companys Form 10-Q filed with the U.S. Securities and Exchange Commission on November 9, 2022. (a) Name of Issuer: ZimVie Inc. (the Company) (b) Address of Issuers Principal Executive Offices: 10225 Westmoor Drive Westminster, CO 80021 (a) Name of Person Filing: Zimmer Biomet Holdings, Inc. (b) Address of Principal Business Office or, if none, Residence: 345 East Main Street Warsaw, IN 46580 (c) Citizenship: Delaware (d)
Title of Class of Securities: Common Stock, par value $0.01 per share (e) CUSIP Number: 98888T107 If this statement is filed pursuant to
Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
Ownership: Explanatory Note: On March 1, 2022, Zimmer Biomet completed the Spinoff through the distribution of 80.3% of the outstanding Company Common Stock to
Zimmer Biomets stockholders. Zimmer Biomet directly owned 5,131,946 shares, or 19.7%, of the outstanding shares of Company Common Stock immediately following the Spinoff and as of December 31, 2022. Amount Beneficially Owned: 5,131,946 shares of Common Stock Percent of Class: 19.7%. The percent of class calculation is based on a denominator of 26,088,272 shares of Company Common Stock outstanding as of
November 4, 2022, as reported in the Companys Form 10-Q filed with the U.S. Securities and Exchange Commission on November 9, 2022. Number of shares as to which such person has: sole power to vote or to direct the vote: 0 In connection with the
Spinoff, Zimmer Biomet and the Company entered into the Stockholder and Registration Rights Agreement, pursuant to which Zimmer Biomet granted to the Company a proxy to vote the shares of Company Common Stock owned by Zimmer Biomet immediately after
the Spinoff in proportion to the votes cast by the Companys other stockholders. As a result, Zimmer Biomet does not exercise voting power over any of the shares of Company Common Stock that it directly owns. shared power to vote or to direct the vote: 0 sole power to dispose or to direct the disposition of: 5,131,946 Pursuant to the
Forward Exchange Agreement, Zimmer Biomet agreed to deliver to a third-party financial institution all of its 5,131,946 shares of Company Common Stock in the first quarter of 2023. Zimmer Biomet has pledged all 5,131,946 of its shares of Company
Common Stock to the financial institution as collateral for its obligations under the Forward Exchange Agreement and the Short-Term Loan. Upon settlement of the Forward Exchange Agreement and the Short-Term Loan, Zimmer Biomet will transfer all of
its shares of Company Common Stock to the financial institution counterparty to settle the Forward Exchange Agreement. shared power to dispose or to direct the disposition of: 0
Ownership of Five Percent or Less of a Class: Not Applicable Ownership of More than Five Percent on Behalf of Another Person: Not Applicable Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the
Parent Holding Company or Control Person: Not Applicable Identification and Classification of Members of the Group: Not Applicable Notice of Dissolution of Group: Not Applicable Certifications: Not Applicable
SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 27, 2023 Chad F. Phipps Senior Vice President, General
Counsel and Secretary
CUSIP No. 98888T107
SCHEDULE 13G
Page
2
of 6 Pages
1
2
3
4
5
6
7
8
9
10
11
12
CUSIP No. 98888T107
SCHEDULE 13G
Page
3
of 6 Pages
Item 1
Item 2
Item 3
(a)
☐
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
(b)
☐
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
☐
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
☐
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
☐
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)
☐
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)
☐
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)
☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
CUSIP No. 98888T107
SCHEDULE 13G
Page
4
of 6 Pages
(i)
☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
☐
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); or
(k)
☐
Group, in accordance with §240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:
___________________________.
Item 4
(a)
(b)
(c)
(i)
(ii)
(iii)
(iv)
CUSIP No. 98888T107
SCHEDULE 13G
Page
5
of 6 Pages
Item 5
Item 6
Item 7
Item 8
Item 9
Item 10
CUSIP No. 98888T107
SCHEDULE 13G
Page
6
of 6 Pages
ZIMMER BIOMET HOLDINGS, INC.
By:
/s/ Chad F. Phipps
1 Year ZimVie Chart |
1 Month ZimVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions